LETTER TO THE EDITOR |
| The first 20% of the full text of this article appears below. |
The authors strongly disagree with Malozowski, because our trial1 was designed to investigate safety, not efficacy. Because a safety signal was not observed, one might question whether the drug was actually delivered to the lungs of the children. This could be proven by a concomitant effect on lung function or symptoms or measuring blood drug levels.
Populations of children with mild asthma are needed for such studies for reasons provided in the US